Search results
Results from the WOW.Com Content Network
Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue [6] and the leading provider of cancer treatments globally. [7] [8] In 2023, the company’s seat in Forbes Global 2000 was 76. [9]
Side effects from the pill, part of Roche's $2.7 billion acquisition of Carmot in December, were mostly gastrointestinal (GI), like those associated with similar drugs.
Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish demand, with experts boosting their sales forecasts for such treatments ...
In 2013, Anderson moved to Switzerland to be head of global product strategy and chief marketing officer of the pharmaceuticals division at the Roche Holding AG. [9] In July 2016, Anderson returned to the U.S. to lead North American Operations at Roche's subsidiary, Genentech. [6] From 2017 to 2018, he was the CEO of Genentech. [6]
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Special pages; Help; Learn to edit; Community portal; Recent changes; Upload file